Please select the option that best describes you:
How would you approach treatment for a HR+ HER2+ clinical T1c N0 male breast cancer?
Answer from: Medical Oncologist at Academic Institution
Extrapolating from female to male breast cancer, I would treat with the regimen of paclitaxel and trastuzumab (Tolaney et al., PMID 30939096), which gives great outcomes [7-year OS was 95% (95% CI, 92.4 to 97.7), and 7-year RFI was 97.5% (95% CI, 95.9 to 99.1)]. After the paclitaxel, I would then ad...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
If clinically node negative, he can receive surgery and then once confirmed to be pT1c pN0, you could provide the TH regimen (weekly paclitaxel x 12 cycles plus trastuzumab for one year). However, my favorite approach would be to give the same regimen in the neoadjuvant setting so that I can re-disc...
Answer from: Medical Oncologist at Community Practice
In a multidisciplinary oncology world, surgical and radiation aspect of this clinical T1cN0 case needs to be addressed as well as adjuvant/neo-adjuvant therapy.Interestingly, men with breast cancer, even in early-stage disease, are being treated with mastectomy and either with axillary LN dissection...